Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Investigación de medicamentos para oncología. Inhibidores de la vía de AKT quinasa con nuevo modo de unión

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20150622001
Publicado:
29/07/2015
Caducidad:
28/07/2016
Resumen:
Una universidad alemana ofrece sustancias para tratamiento oncológico: inhibidores de AKT covalentes-alostéricos con nuevo modo de acción y tiempos de residencia ampliados del blanco del medicamento. Gracias al uso de estas sustancias, la proteína AKT, que se ha identificado como un blanco en la terapia contra el cáncer, se une de forma irreversible con la más alta afinidad. La universidad busca compañías farmacéuticas con el fin de establecer acuerdos de licencia.

Details

Tittle:
Oncology drug research: Inhibitors of the kinase Akt pathway with a new mode of binding
Summary:
A German university offers substances for oncology therapy. These are covalent-allosteric Akt inhibitors - with a new mode of action and extended drug-target residence times. By employing these substances, Akt, which has in the past been identified as a cancer therapy target, is bound irreversibly with highest affinity. Pharmaceutical companies are sought for license agreements.
Description:
The development of new drugs in oncology has shifted from unspecific cytotoxic drugs to highly specific substances with known targets and modes of action. A prominent group of these target specific cancer drugs are the kinase inhibitors.

A German university invented substances that are inhibitors of the kinase AKT which is involved in several pathways regulating cell functions in cancer, e.g. survival and proliferation. AKT is a serine/threonine kinase and oncogene that has already been identified and addressed as a target in cancer therapy by several pharmaceutical companies.

The particular novelty of the invented compounds is based on their combined covalent-allosteric binding mode. These are first-in-class modulators of AKT with a novel mode of inhibition. Covalent-allosteric inhibitors show extended drug-target residence times.

Partners are sought for license agreements. The invented substances are of high interest for any pharmaceutical company with an oncology pipeline and they are of special advantage for those who seek to improve, broaden or supplement their kinase inhibitor portfolio with inhibitors that bind AKT irreversibly.
Advantages and Innovations:
· For the first time: combined covalent-allosteric binding mode
· The inhibitors bind AKT irreversibly and specifically with highest affinity
Stage of Development:
Prototype available for demonstration
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
European and US patent applied for.

Partner sought

Type and Role of Partner Sought:
Pharmaceutical companies with activities in oncology are sought for licensing agreements to use the invented substances in their cancer drug research and production and to supplement their kinase inhibitor portfolio.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos
06001013 Tecnología médica / ingeniería biomédica